PE20020447A1 - Ligandos receptores de melanocortina - Google Patents

Ligandos receptores de melanocortina

Info

Publication number
PE20020447A1
PE20020447A1 PE2001000965A PE2001000965A PE20020447A1 PE 20020447 A1 PE20020447 A1 PE 20020447A1 PE 2001000965 A PE2001000965 A PE 2001000965A PE 2001000965 A PE2001000965 A PE 2001000965A PE 20020447 A1 PE20020447 A1 PE 20020447A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
halo
heterocycle
halves
Prior art date
Application number
PE2001000965A
Other languages
English (en)
Inventor
Frank Hallock Ebetino
Adam W Mazur
Hayes Jeffrey Charles
Feng Nmn Wang
Mark Gregory Solinsky
Anny-Odile Colson
Qishen Lin
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20020447A1 publication Critical patent/PE20020447A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)

Abstract

SE REFIERE A PEPTIDOS DE FORMULA I DONDE X ES H, F, OR1, SR1, NR1R1', ENTRE OTROS; R2 ES H, HALOALQUILO, HETEROALQUILO; R2 Y R2 CONSECUTIVOS O R2 Y R3 FORMAN CARBOCICLO, HETEROCICLO; R2, X, Z1, MITAD DE R5 FORMAN CARBOCICLO, HETEROCICLO FUSIONADO AL ANILLO J; R2 Y R7 PUEDEN ESTAR FUSIONADOS A Ar; R2, Z2, Z3, R8 FORMAN CARBOCICLO, HETEROCICLO; Z1, Z2, Z3 SON OCR3R3a, CR3R3aO, SOaCR3R3a, CR3R3aSOb; a ES 0-2; b ES 0-2; R3, R3a, R3b SON H, OH, ALCOXI, ARILOXI, ENTRE OTROS; p ES 0-5; p>0; R4 Y R4' SON H, ALQUILO, ARILO, HALO, ENTRE OTROS; p>1, DOS MITADES DE R4 FORMAN HETEROCICLOALQUILO, CICLOALQUILO, ARILO; R5 ES H, OH, HALO, TIOL, OR12, SR12, SO2NR12, R12'; R12 Y R12' SON H, ALQUILO, ARILO; q ES 0-5; q>O; R6, R6' SON H, ALQUILO, ACILO, HALO, OH; ENTRE OTROS; Ar ES ARILO, HETEROARILO, FENILO, TIOFENO, ENTRE OTROS; R7 ES H, HALO, NR13R13', ALQUILO, ACILO; r ES 0-7; R8 Y R8' SON H, ALQUILO, HALO, ENTRE OTROS; r>1, DOS MITADES DE R8 FORMAN UN HETEROCICLO, ALQUILO, ENTRE OTROS; B ES NR14C(=NR15), =O, (=S)NR16R17, NR20R21, CN; s ES 0-5; s>0, R9 Y R9' SON H, ALQUILO, ARILO, HALO, ENTRE OTROS; s>1, DOS MITADES R9 FORMAN HETEROCICLO-ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS; R10 ES ANILLO ARILO, BICICLICO, HETEROARILO; D ES H, F, OH, TIOL, ACILTIO, ENTRE OTROS. LOS COMPUESTOS SON LIGANDOS DE LOS RECEPTORES DE MELANOCORTINA MC-4, MC-3 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE OBESIDAD, ANOREXIA, CAQUEXIA, RESISTENCIA A LA INSULINA, PRESION SANGUINEA ELEVADA, HIPERTENSION, DISLIPIDEMIA
PE2001000965A 2000-09-27 2001-09-27 Ligandos receptores de melanocortina PE20020447A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23585800P 2000-09-27 2000-09-27

Publications (1)

Publication Number Publication Date
PE20020447A1 true PE20020447A1 (es) 2002-07-02

Family

ID=22887187

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000965A PE20020447A1 (es) 2000-09-27 2001-09-27 Ligandos receptores de melanocortina

Country Status (19)

Country Link
EP (1) EP1409540A2 (es)
JP (1) JP2004509974A (es)
KR (1) KR100519204B1 (es)
CN (1) CN1571796A (es)
AR (1) AR030806A1 (es)
AU (2) AU2001296313B2 (es)
BR (1) BR0114257A (es)
CA (1) CA2420045A1 (es)
CZ (1) CZ2003788A3 (es)
HU (1) HUP0303085A2 (es)
IL (1) IL154437A0 (es)
MX (1) MXPA03002691A (es)
NO (1) NO20031287D0 (es)
NZ (1) NZ524190A (es)
PE (1) PE20020447A1 (es)
PL (1) PL362003A1 (es)
RU (1) RU2246501C2 (es)
WO (1) WO2002026774A2 (es)
ZA (1) ZA200301561B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
WO2007116360A2 (en) 2006-04-07 2007-10-18 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008107362A2 (en) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Stabiliser and inhibitors of factor vii
WO2009152079A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011060355A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2
MX2012005862A (es) 2009-11-23 2012-09-07 Palatin Technologies Inc Peptidos ciclicos especificos del receptor de melanocortina-1.
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
US10347423B2 (en) 2014-05-12 2019-07-09 Capacitor Sciences Incorporated Solid multilayer structure as semiproduct for meta-capacitor
US10340082B2 (en) 2015-05-12 2019-07-02 Capacitor Sciences Incorporated Capacitor and method of production thereof
KR102331588B1 (ko) 2014-05-12 2021-11-30 캐패시터 사이언시스 인코포레이티드 에너지 저장 디바이스 및 이의 생산 방법
AU2015343211A1 (en) 2014-11-04 2017-04-27 Capacitor Sciences Incorporated Energy storage devices and methods of production thereof
KR20170118764A (ko) 2015-02-26 2017-10-25 캐패시터 사이언시스 인코포레이티드 자기-회복 커패시터 및 이들의 생산 방법
US9932358B2 (en) * 2015-05-21 2018-04-03 Capacitor Science Incorporated Energy storage molecular material, crystal dielectric layer and capacitor
US9941051B2 (en) 2015-06-26 2018-04-10 Capactor Sciences Incorporated Coiled capacitor
US10026553B2 (en) 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor
US10305295B2 (en) 2016-02-12 2019-05-28 Capacitor Sciences Incorporated Energy storage cell, capacitive energy storage module, and capacitive energy storage system
US9978517B2 (en) 2016-04-04 2018-05-22 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US10153087B2 (en) 2016-04-04 2018-12-11 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US10395841B2 (en) 2016-12-02 2019-08-27 Capacitor Sciences Incorporated Multilayered electrode and film energy storage device
CN106966927B (zh) * 2017-04-13 2018-10-09 菲立化学工程（上海）有限公司 一种抗艾滋病药物中间体重氮酮与氯酮的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350430B1 (en) * 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
KR100558131B1 (ko) * 1999-03-29 2006-03-10 더 프록터 앤드 갬블 캄파니 멜라노코르틴 수용체 리간드를 함유하는 약제학적 조성물및 멜라노코르틴 수용체 리간드를 함유하는 약제의제조방법
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction

Also Published As

Publication number Publication date
KR100519204B1 (ko) 2005-10-06
AU2001296313B2 (en) 2005-06-02
ZA200301561B (en) 2004-03-10
HUP0303085A2 (hu) 2003-12-29
NO20031287L (no) 2003-03-20
RU2246501C2 (ru) 2005-02-20
JP2004509974A (ja) 2004-04-02
MXPA03002691A (es) 2003-06-06
BR0114257A (pt) 2003-07-01
IL154437A0 (en) 2003-09-17
CN1571796A (zh) 2005-01-26
PL362003A1 (en) 2004-10-18
KR20030061814A (ko) 2003-07-22
NZ524190A (en) 2004-09-24
WO2002026774A2 (en) 2002-04-04
NO20031287D0 (no) 2003-03-20
AU9631301A (en) 2002-04-08
CZ2003788A3 (cs) 2003-08-13
CA2420045A1 (en) 2002-04-04
AR030806A1 (es) 2003-09-03
EP1409540A2 (en) 2004-04-21
WO2002026774A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
PE20020447A1 (es) Ligandos receptores de melanocortina
PE20011083A1 (es) 2-indolinas sustituidas con pirroles inhibidoras de proteinquinasas
CO5721000A2 (es) (tiazol-2-il)-amida o sulfonamida substituida como activado- res de glicocinasa utiles en el tratamiento de diabetes de tipo 2
CA2430978A1 (en) Vla-4 inhibitors
DE69613240T2 (de) N-aminoalkylfluorencarboxamide, neue klasse von dopaminerezeptor subtype spezifische liganden
CY1107679T1 (el) Παραγωγα οξαζολυλ-αρυλ προπιονικου οξεος και χρηση αυτων σαν αγωνιστες ppar
CO5251458A1 (es) Nuevos compuestos
GB9225492D0 (en) Amine derivatives
DE69719765D1 (de) 4-aminoethoxy-indolderivate als dopamin d2 agonisten und als 5ht1a liganden
TW200602317A (en) Novel androgens
KR940014384A (ko) 항바이러스제로서의 페녹시- 및 페녹시알킬-피페리딘
TW197421B (es)
DE60008917D1 (de) Neue 1,8-naphtyridin-2(1h)-on-derivate
PE20011137A1 (es) Inhibidores de las metaloproteasas que contienen cadenas laterales heterociclicas n-sustituidas
DE69822478D1 (de) Thiophen- und benzothiophenderivate, deren verwendung und sie enthaltende zubereitung
DK709088A (da) Thiolderivater
JO2235B1 (en) Derivatives of phenyl
EP1092737A3 (en) Catalyst composition for the production of a polyurethane resin, and method for producing a polyurethane resin
ATE207058T1 (de) Amine derivate, ihre herstellung und anwendung
EP1604983A4 (en) Receptor Antagonists
EP1864977A4 (en) NOVEL CYCLIC COMPOUNDS HAVING A PYRIMIDINYLALKYLTHIO GROUP
MY140027A (en) Cyclic amine derivatives, process for their preparation and pharmaceuticals containing them
ATE188967T1 (de) Übergangsmetallverbindungen
KR960022504A (ko) 1-옥소-2-(페닐술포닐아미노) 펜틸피페리딘 유도체, 그것의 제법 및 치료학적 적용
ATE227284T1 (de) 4-aminoethoxy-indolonderivate als dopamin d2 agonisten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal